SAB Biotherapeutics, Inc. (SABS) Stock

Healthcare · Biotechnology · Member of Other US Stocks

SAB Biotherapeutics, Inc. (SABS) closed at USD 2.59 on 2026-10-15, a change of -14.8 % over the past year, with a market capitalization of USD 230.2M.

SAB Biotherapeutics, Inc. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

SAB Biotherapeutics, Inc. key figures

Previous close

USD 2.59 (2026-10-15)

1-year change

-14.8 %

Market cap

USD 230.2M

Enterprise value

USD 132.7M

P/E ratio (trailing)

-1.96

P/E ratio (forward)

-2.65

EPS (trailing)

-1.29

EPS (forward)

-0.95

PEG ratio

n/a

Price to book

0.98

Revenue growth

n/a

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

7.57

Employees

86

Analyst consensus (third-party)

none

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About SAB Biotherapeutics, Inc.

SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases in the United States. Its lead product candidate is SAB-142, a potentially disease-modifying and redosable immunotherapy in clinical development for the treatment of autoimmune type 1 diabetes in Phase 2b clinical trials. The company was founded in 2014 and is headquartered in Miami Beach, Florida.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for SAB Biotherapeutics, Inc. and compare it with other stocks.